Safety and preliminary activity of naptumomab in combination with durvalumab presented at AACR 2023 - Marketscreener.com
| ACTI Stock | SEK 0.27 0.02 8.00% |
Slightly above 55% of Active Biotech's private investors are presently thinking to get in. The analysis of current outlook of investing in Active Biotech AB suggests that some traders are interested regarding Active Biotech's prospects. Active Biotech's investing sentiment can be driven by a variety of factors including economic data, Active Biotech's earnings reports, geopolitical events, and overall market trends.
Active |
Safety and preliminary activity of naptumomab in combination with durvalumab presented at AACR 2023 Marketscreener.com
Read at news.google.com
 |
Active Biotech Fundamental Analysis
We analyze Active Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Active Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Active Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Sales
Price To Sales Comparative Analysis
Active Biotech is currently under evaluation in price to sales category among its peers. Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Active Biotech AB Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Active Biotech stock to make a market-neutral strategy. Peer analysis of Active Biotech could also be used in its relative valuation, which is a method of valuing Active Biotech by comparing valuation metrics with similar companies.
Peers
Active Biotech Related Equities
| BIOA-B | BioArctic | 2.99 | ||||
| HNSA | Hansa Biopharma | 0.12 | ||||
| CANTA | Cantargia | 1.64 | ||||
| ONCO | Oncopeptides | 2.37 | ||||
| BINV | BioInvent International | 2.71 |
Additional Tools for Active Stock Analysis
When running Active Biotech's price analysis, check to measure Active Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Active Biotech is operating at the current time. Most of Active Biotech's value examination focuses on studying past and present price action to predict the probability of Active Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Active Biotech's price. Additionally, you may evaluate how the addition of Active Biotech to your portfolios can decrease your overall portfolio volatility.